Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Значение эффективной блокады ренин-ангиотензин-альдостероновой системы с помощью прямого ингибирования ренина у пациентов с артериальной гипертонией и избыточной массой тела
Значение эффективной блокады ренин-ангиотензин-альдостероновой системы с помощью прямого ингибирования ренина у пациентов с артериальной гипертонией и избыточной массой тела
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Archard V et al. Renin receptor expression in human adipose tissue Am J Physiol Regulatory Integrative Comp Physiol 2005; 292: 274–82.
2. Gorostidi M, Prieto MA, Marin R et al. Renal insufficiency is the most prevalent target-organ disease in primary care attended essential hypertension. AHJ 2005; 18 (5, Pt. 2).
3. Bohm M, Thoenes M, Danchin W et al. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens 2007; 25: 2317–24.
4. Verma A et al. Neurohumoral effects of an oral direct renin inhibitor in patients with left ventricular hypertrophy: The Aliskiren in left ventricular hypertrophy (ALLAY) trial. ESH Congress materials, Milan, Italy, 12–16 June 2009. S 314 abs 7B.4.
5. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). Кардиоваск. тер. и проф. 2008; Прил. 2.
6. ESH-ESC Guidelines Committee. 2009 guidelines for the management of hypertension. J Hypertension 2009; 27. 000–000.
7. Uresin Y et al. Aliskiren monotherapy lowers blood pressure more effectively than ramipril monotherapy in patients with diabetes and grade 2 hypertension: subgroup analysis of an 8-week, double-blind trial. J Hypertens 2008; 26 (suppl. 1): S479.
8. Andersen K et al. Comparative efficacy and safety of Aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month randomized, double-blind trial. J Hypertens 2008; 26: 589–99.
9. O'Brien E, Barton J, Nussberger J et al. Aliskiren reduces blood pressure and suppresses plasma rennin activity in combination with thiazide diuretic, an angiotensin-converting enzyme ingibitor, or an angiotensin receptor blocker. Hypertension 2007; 49: 276–284.
10. Villami A, Chrysant SG, Calhoun D et al. Renin ingibitor with aliskiren provides additive antihypertensive efficancy when used in combination with hydrochlorthiazide. J Hypertens 2007; 25: 217–26.
11. Littlejohn TW 3rd, Trenkwalder P, Hollanders G et al. Longterm safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009; 25: 951–59.
12. Parving HH, Persson F, Lewis JB et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–46.
13. Seed A, Gardner R, McMurray J et al. Neurohumoral effects of the new orally active inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail 2007; 9: 1120–7.
14. Gardner RS, Ozalp F, Murday AJ et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Hert J 2003; 24: 1735–43.
15. Weir MR, Bush C, Anderson DR et al. Antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007; 1 (4):264–77.
16. Bramlage P, Pittrow D, Wittchen HU et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. AJH 2004; 17: 904–10.
17. Prescott MF, Boye SW, Breton S et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren when added to hydrochlorthiazide treatment in patients with extreme obesity and hypertension. J Hypertens 2009; 69:833–84.
18. Jordan J, Engely S, Boye SW et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. J Hypertens 2007; 49:1047–55.
19. Masur K, Thevenod F, Zanker KS et al. Diabetes and cancer: epidemiological evidence and molecular links. Front Diabetes. Basel, Karger, 2008; 19: 1–18.
20. Persson F, Rossing P, Renhard H et al. Renoprotective effects of the direct renin inhibitor aliskiren, irbesartan and the combination in patients with type 2 diabetes, hypertension and albuminuria. Poster presentation at the American Diabetes Association meeting, San Francisco, USA, June 6–10 2008.
21. Pitt B, McMurray J, Latini R et al. Abstract 2491: Neurohumoral Effects Of A New Oral Direct Renin Inhibitor In Stable Heart Failure: The Aliskiren Observation Of Heart Failure Treatment Study (ALOFT). Circulation 2007; 116: II 549.
22. Solomon SD, Appelbaum E, Manning WJ et al. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct rennin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530–7.
2. Gorostidi M, Prieto MA, Marin R et al. Renal insufficiency is the most prevalent target-organ disease in primary care attended essential hypertension. AHJ 2005; 18 (5, Pt. 2).
3. Bohm M, Thoenes M, Danchin W et al. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens 2007; 25: 2317–24.
4. Verma A et al. Neurohumoral effects of an oral direct renin inhibitor in patients with left ventricular hypertrophy: The Aliskiren in left ventricular hypertrophy (ALLAY) trial. ESH Congress materials, Milan, Italy, 12–16 June 2009. S 314 abs 7B.4.
5. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). Кардиоваск. тер. и проф. 2008; Прил. 2.
6. ESH-ESC Guidelines Committee. 2009 guidelines for the management of hypertension. J Hypertension 2009; 27. 000–000.
7. Uresin Y et al. Aliskiren monotherapy lowers blood pressure more effectively than ramipril monotherapy in patients with diabetes and grade 2 hypertension: subgroup analysis of an 8-week, double-blind trial. J Hypertens 2008; 26 (suppl. 1): S479.
8. Andersen K et al. Comparative efficacy and safety of Aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month randomized, double-blind trial. J Hypertens 2008; 26: 589–99.
9. O'Brien E, Barton J, Nussberger J et al. Aliskiren reduces blood pressure and suppresses plasma rennin activity in combination with thiazide diuretic, an angiotensin-converting enzyme ingibitor, or an angiotensin receptor blocker. Hypertension 2007; 49: 276–284.
10. Villami A, Chrysant SG, Calhoun D et al. Renin ingibitor with aliskiren provides additive antihypertensive efficancy when used in combination with hydrochlorthiazide. J Hypertens 2007; 25: 217–26.
11. Littlejohn TW 3rd, Trenkwalder P, Hollanders G et al. Longterm safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009; 25: 951–59.
12. Parving HH, Persson F, Lewis JB et al. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–46.
13. Seed A, Gardner R, McMurray J et al. Neurohumoral effects of the new orally active inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail 2007; 9: 1120–7.
14. Gardner RS, Ozalp F, Murday AJ et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Hert J 2003; 24: 1735–43.
15. Weir MR, Bush C, Anderson DR et al. Antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007; 1 (4):264–77.
16. Bramlage P, Pittrow D, Wittchen HU et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. AJH 2004; 17: 904–10.
17. Prescott MF, Boye SW, Breton S et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren when added to hydrochlorthiazide treatment in patients with extreme obesity and hypertension. J Hypertens 2009; 69:833–84.
18. Jordan J, Engely S, Boye SW et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. J Hypertens 2007; 49:1047–55.
19. Masur K, Thevenod F, Zanker KS et al. Diabetes and cancer: epidemiological evidence and molecular links. Front Diabetes. Basel, Karger, 2008; 19: 1–18.
20. Persson F, Rossing P, Renhard H et al. Renoprotective effects of the direct renin inhibitor aliskiren, irbesartan and the combination in patients with type 2 diabetes, hypertension and albuminuria. Poster presentation at the American Diabetes Association meeting, San Francisco, USA, June 6–10 2008.
21. Pitt B, McMurray J, Latini R et al. Abstract 2491: Neurohumoral Effects Of A New Oral Direct Renin Inhibitor In Stable Heart Failure: The Aliskiren Observation Of Heart Failure Treatment Study (ALOFT). Circulation 2007; 116: II 549.
22. Solomon SD, Appelbaum E, Manning WJ et al. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct rennin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530–7.
Авторы
В.Б.Мычка, М.Ю.Кириллова, Ю.В.Жернакова, Я.Р.Богачев, И.Е.Чазова
Отдел системных гипертензий Института клинической кардиологии им. А.Л.Мясникова, ФГУ Российский кардиологический научно-производственный комплекс Росмедтехнологий
Отдел системных гипертензий Института клинической кардиологии им. А.Л.Мясникова, ФГУ Российский кардиологический научно-производственный комплекс Росмедтехнологий
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.